Axsome Therapeutics, Inc. (AXSM) News
Filter AXSM News Items
AXSM News Results
|Loading, please wait...|
AXSM News Highlights
- For AXSM, its 30 day story count is now at 6.
- Over the past 24 days, the trend for AXSM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ALB, CNS and INSP are the most mentioned tickers in articles about AXSM.
Latest AXSM News From Around the Web
Below are the latest news stories about AXSOME THERAPEUTICS INC that investors may wish to consider to help them evaluate AXSM as an investment opportunity.
Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ETNEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full year of 2022 on Monday, Feb. 27, 2023, before the opening of the U.S. financial markets. Axsome’s management
Long-term investors looking to overcome the effects of inflation can find some satisfaction from quality growth stocks, especially from companies generating triple-digit growth in revenue and share-price appreciation. Shares of Inspire Medical Systems (NYSE: INSP), Axsome Therapeutics (NASDAQ: AXSM), and Abermarle (NYSE: ALB) can all be purchased for under $300. All three companies have had triple-digit percentage revenue and share-price growth over the past five years.
It's important to remember, though, that today's economic troubles and stock market downturn are temporary. Certain growth stocks may suffer in this sort of context. One is a medical technology company that's set to report record earnings.
Investors bought certain stocks hand over fist. In most cases, these particular companies offered investors a solid reason to be optimistic about their future. Up-and-coming biotech Axsome Therapeutics (NASDAQ: AXSM) commercialized its first two products.
No matter the macro environment, individualized bull markets happen all the time.
After all, many currently well-established companies were once small- or mid-cap stocks. Axsome Therapeutics is a mid-cap drugmaker coming off a solid performance in 2022, during which its shares more than doubled. The company could carry this momentum into this year.
Axsome Therapeutics (NASDAQ: AXSM) soared more than 100%. Vertex submitted a potential blockbuster in a new treatment area to regulators. Let's check out why Axsome and Vertex are still stocks to buy.
The stock market has been performing better recently, with the S&P 500 up by nearly 5% in the past three months, although it remains down 18% over the past year. Economic or market conditions could worsen and drag down the stock market. Regardless of potentially unforeseen dynamics that could affect equity markets in 2023, investors should continue to invest in solid stocks that can grow long after the current downturn is behind us.
Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.
It has been a rough year for biotech stocks. It doesn't make sense to write off the entire biotech sector, however. Axsome Therapeutics (NASDAQ: AXSM) and Exelixis (NASDAQ: EXEL) are growing revenue and net income, making the two mid-cap biotech stocks attractive long-term buys.